论文部分内容阅读
10月下旬,扬子江药业集团与中美冠科生物技术(太仓)有限公司举行研发合作签约仪式在海燕大酒店举行。集团北京海燕药业副总经理石和鹏博士、中美冠科生物技术(太仓)有限公司石全博士作为双方代表签约。太仓市政协主席宋建中、政府秘书长陆定峰等领导,以及扬子江药业集团董事长徐镜人等共同出席并见证了签约合作。中美冠科是世界著名的生物制药
In late October, the Yangtze River Pharmaceutical Group and Sino-US crown Branch Biotechnology (Taicang) Co., Ltd. held a signing ceremony of R & D cooperation held at the Haiyan Hotel. Dr. Shi Hepeng, Group Vice President of Beijing Swallow Pharmaceutical Co., Ltd., and Dr. Shi Quan, a Sino-U.S. Cornell Biotech (Taicang) Co., Ltd., signed on behalf of both parties. Song Jianzhong, chairman of Taicang CPPCC and Lu Dingfeng, secretary-general of the government, and Xu Jingren, chairman of the Yangtze River Pharmaceutical Group attended the meeting and witnessed the signing of the cooperation. China and the United States crown is the world’s leading biopharmaceuticals